Pfizer’s finally getting what it always wanted in U.S. tax reform. And now, all eyes are on what it will do next. Regarding M&A, CEO Ian Read says the new cash won’t make any difference to its megadeal plans.
More: What will Pfizer do with tax reform? It won't revive a split, CFO says